Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Daiichi Sankyo filed a new drug application for its EZH1/2 dual inhibitor valemetostat in Japan on December 28 for the treatment of relapsed/refractory adult T-cell leukemia-lymphoma (ATL). The submission is based on data from a Japan PII study targeting this…
To read the full story
Related Article
- Daiichi Sankyo’s Valemetostat Logs 48% Response in Japan ATL Study
December 14, 2021
- Daiichi Sankyo, France/Belgium Lymphoma Group to Collaborate on Valemetostat Trial
February 26, 2021
- 1st Patient Dosed in Japan PII for Daiichi Sankyo’s ATL Drug
December 11, 2019
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





